Whanin Pharm seeking suit to confirm non-presence of liabilities over Merck-Lipha

Published: 2003-12-03 06:56:00

Updated: 2003-12-03 06:56:00

Whanin Pharm said it is seeking a local court's ruling over the liabilities incurred out of an annulled secrecy agreement executed earlier with France-based Merck-Lipha, while

According to Whanin, the company had aimed to introduce acamprosate, a medication for alcohol abuse and alcoholism tr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK